Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.
Immunis has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in July 2024.
Immunis's investors include Remiges Ventures, Bold Capital Partners, Ironwood Ventures, Lifespan Vision Ventures, JLS Fund.
Immunis is headquartered in Irvine, United States.
Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.
Immunis is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immunis — Funding & Investors." VCBacked, July 1, 2024, https://www.vcbacked.co/company/immunis. Accessed August 1, 2026.
VCBacked. (2024). Immunis — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/immunis
{{cite web |title=Immunis — Funding & Investors |url=https://www.vcbacked.co/company/immunis |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated